Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | F9 | P00740 | 4/20 | 0.49 |
| ▸ | F10 | P00742 | 3/20 | 0.49 |
| ▸ | C1S | P09871 | 2/20 | 0.49 |
| ▸ | CFD | P00746 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 12/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748560 | 0.81 | CYP1A2 (0.54) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL13709643 | 0.80 | F9 (0.66) | SMN1; SMN2F9F10C1SCFD | |
| SCHEMBL3741582 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL13709596 | 0.77 | F9 (0.59) | F9F10C1SCFDHDAC6 | |
| SCHEMBL3746579 | 0.75 | LTA4H (0.49) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL11471037 | 0.75 | CYP1A2 (0.73) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL13709512 | 0.73 | F9 (0.56) | CYP1A2CYP3A4CYP2C19F9F10 | |
| SCHEMBL563279 | 0.72 | F9 (0.65) | F9F10C1SCFDHDAC6 | |
| SCHEMBL30583137 | 0.72 | F9 (0.65) | F9F10C1SCFDHDAC6 | |
| SCHEMBL8683981 | 0.71 | CYP1A2 (0.68) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | F12, F5, F3 | CYP1A2 105/4885CYP3A4 258/4885CYP2D6 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.